Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Coherus BioSciences (NASDAQ: CHRS) announced its participation in the 2024 Citi Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus BioSciences (NASDAQ: CHRS) announced its participation in the 2024 Citi Global Healthcare Conference. Dr. Theresa LaVallee, Chief Development Officer, will be a panelist on the Novel Mechanisms in Oncology Panel scheduled for December 3, 2024, at 3:15 p.m. ET. The panel discussion will be available via webcast through the Investor Events and Presentations section of the Coherus website.
Details
News Market Reaction – CHRS
The recorded move for CHRS in the trading session of this news was -3.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
The panel discussion will be accessible via webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations.
Coherus Contact Information:
For Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.